BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 26037121)

  • 21. Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.
    Hussack G; Tanha J
    Toxins (Basel); 2010 May; 2(5):998-1018. PubMed ID: 22069622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bezlotoxumab prevents extraintestinal organ damage induced by
    Mileto SJ; Hutton ML; Walton SL; Das A; Ioannidis LJ; Ketagoda D; Quinn KM; Denton KM; Hansen DS; Lyras D
    Gut Microbes; 2022; 14(1):2117504. PubMed ID: 36045589
    [No Abstract]   [Full Text] [Related]  

  • 23. Genomic and Phenotypic Characterization of the Nontoxigenic Clostridioides difficile Strain CCUG37785 and Demonstration of Its Therapeutic Potential for the Prevention of C. difficile Infection.
    Wang S; Heuler J; Wickramage I; Sun X
    Microbiol Spectr; 2022 Apr; 10(2):e0178821. PubMed ID: 35315695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxin B is essential for virulence of Clostridium difficile.
    Lyras D; O'Connor JR; Howarth PM; Sambol SP; Carter GP; Phumoonna T; Poon R; Adams V; Vedantam G; Johnson S; Gerding DN; Rood JI
    Nature; 2009 Apr; 458(7242):1176-9. PubMed ID: 19252482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
    Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
    Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.
    Sirard S; Valiquette L; Fortier LC
    J Clin Microbiol; 2011 Dec; 49(12):4040-6. PubMed ID: 21956985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human intestinal enteroids as a model of
    Engevik MA; Danhof HA; Chang-Graham AL; Spinler JK; Engevik KA; Herrmann B; Endres BT; Garey KW; Hyser JM; Britton RA; Versalovic J
    Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G870-G888. PubMed ID: 32223302
    [No Abstract]   [Full Text] [Related]  

  • 28. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.
    Steele J; Parry N; Tzipori S
    Gut Microbes; 2014; 5(1):53-7. PubMed ID: 24394234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CdtR Regulates TcdA and TcdB Production in Clostridium difficile.
    Lyon SA; Hutton ML; Rood JI; Cheung JK; Lyras D
    PLoS Pathog; 2016 Jul; 12(7):e1005758. PubMed ID: 27414650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plakoglobin and High-Mobility Group Box 1 Mediate Intestinal Epithelial Cell Apoptosis Induced by Clostridioides difficile TcdB.
    Li Y; Xu W; Ren Y; Cheung HC; Huang P; Kaur G; Kuo CJ; McDonough SP; Fubini SL; Lipkin SM; Deng X; Chang YF; Huang L
    mBio; 2022 Oct; 13(5):e0184922. PubMed ID: 36043787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
    Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
    Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequence variation in tcdA and tcdB of Clostridium difficile: ST37 with truncated tcdA is a potential epidemic strain in China.
    Du P; Cao B; Wang J; Li W; Jia H; Zhang W; Lu J; Li Z; Yu H; Chen C; Cheng Y
    J Clin Microbiol; 2014 Sep; 52(9):3264-70. PubMed ID: 24958798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant.
    Aminzadeh A; Hilgers L; Paul Platenburg P; Riou M; Perrot N; Rossignol C; Cauty A; Barc C; Jørgensen R
    Vaccine; 2024 Mar; 42(7):1582-1592. PubMed ID: 38336558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo.
    Kordus SL; Kroh HK; Rodríguez RC; Shrem RA; Peritore-Galve FC; Shupe JA; Wadzinski BE; Lacy DB; Spiller BW
    PLoS Pathog; 2023 Oct; 19(10):e1011496. PubMed ID: 37871122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrinsic Toxin-Derived Peptides Destabilize and Inactivate
    Larabee JL; Bland SJ; Hunt JJ; Ballard JD
    mBio; 2017 May; 8(3):. PubMed ID: 28512094
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibition of Clostridium difficile TcdA and TcdB toxins with transition state analogues.
    Paparella AS; Aboulache BL; Harijan RK; Potts KS; Tyler PC; Schramm VL
    Nat Commun; 2021 Nov; 12(1):6285. PubMed ID: 34725358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
    Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
    J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
    Romano MR; Leuzzi R; Cappelletti E; Tontini M; Nilo A; Proietti D; Berti F; Costantino P; Adamo R; Scarselli M
    Toxins (Basel); 2014 Apr; 6(4):1385-96. PubMed ID: 24759173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.
    Maynard-Smith M; Ahern H; McGlashan J; Nugent P; Ling R; Denton H; Coxon R; Landon J; Roberts A; Shone C
    Vaccine; 2014 Feb; 32(6):700-5. PubMed ID: 24342251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of the Endosomal Anion/Proton Exchanger ClC-5 Increases Cell Susceptibility toward
    Ruhe F; Olling A; Abromeit R; Rataj D; Grieschat M; Zeug A; Gerhard R; Alekov A
    Front Cell Infect Microbiol; 2017; 7():67. PubMed ID: 28348980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.